Trial · NCT04445987
Adverse events60
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 60
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | COVID-19 | Infections and infestations | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | 3 | 75 | |
| other | COVID-19 | Infections and infestations | Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | 3 | 58 | |
| other | COVID-19 | Infections and infestations | Cohort 2 Group 4: De Novo Participants | 9 | 267 | |
| other | COVID-19 | Infections and infestations | Cohort 1 Group 2: ARQ-154-116 Rollover | 0 | 8 | |
| other | Urinary tract infection | Infections and infestations | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | 0 | 75 | |
| other | Urinary tract infection | Infections and infestations | Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | 4 | 58 | |
| other | Urinary tract infection | Infections and infestations | Cohort 2 Group 4: De Novo Participants | 3 | 267 | |
| other | Urinary tract infection | Infections and infestations | Cohort 1 Group 2: ARQ-154-116 Rollover | 0 | 8 | |
| other | Weight decreased | Investigations | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | 0 | 75 | |
| other | Weight decreased | Investigations | Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | 0 | 58 | |
| other | Weight decreased | Investigations | Cohort 2 Group 4: De Novo Participants | 0 | 267 | |
| other | Weight decreased | Investigations | Cohort 1 Group 2: ARQ-154-116 Rollover | 1 | 8 | |
| other | Tic | Psychiatric disorders | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | 0 | 75 | |
| other | Tic | Psychiatric disorders | Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | 0 | 58 | |
| other | Tic | Psychiatric disorders | Cohort 2 Group 4: De Novo Participants | 0 | 267 | |
| other | Tic | Psychiatric disorders | Cohort 1 Group 2: ARQ-154-116 Rollover | 1 | 8 | |
| other | Dyspepsia | Gastrointestinal disorders | Cohort 1 Group 1: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | 0 | 75 | |
| other | Dyspepsia | Gastrointestinal disorders | Cohort 2 Group 3: ARQ-154-203 Roflumilast Foam 0.3% Without Treatment Gap | 0 | 58 | |
| other | Dyspepsia | Gastrointestinal disorders | Cohort 2 Group 4: De Novo Participants | 0 | 267 | |
| other | Dyspepsia | Gastrointestinal disorders | Cohort 1 Group 2: ARQ-154-116 Rollover | 1 | 8 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04445987/events